| Literature DB >> 30113144 |
Kyoung Hwa Ha1,2, Yong Ho Lee3, Sun Ok Song4, Jae Woo Lee5, Dong Wook Kim6, Kyung Hee Cho7, Dae Jung Kim1,8.
Abstract
BACKGROUND: A diabetes risk score in Korean adults was developed and validated.Entities:
Keywords: Diabetes mellitus; Korea; Risk assessment; Risk factors
Year: 2018 PMID: 30113144 PMCID: PMC6202558 DOI: 10.4093/dmj.2018.0014
Source DB: PubMed Journal: Diabetes Metab J ISSN: 2233-6079 Impact factor: 5.376
Baseline characteristics of participants in development and validation cohorts at study entry
| Variable | Development cohort | Validation cohort | ||
|---|---|---|---|---|
| Men ( | Women ( | Men ( | Women ( | |
| Age, yr | 51.2±9.2 | 52.5±9.6 | 50.4±8.4 | 51.3±8.8 |
| Family history of diabetes | 11,164 (5.8) | 10,461 (6.2) | 301 (9.5) | 403 (11.5) |
| Alcohol intake | ||||
| Abstinent | 66,159 (34.6) | 138,003 (82.1) | 960 (30.3) | 2,597 (74.3) |
| Low-medium | 112,992 (59.1) | 29,589 (17.6) | 1,726 (54.6) | 838 (24.0) |
| High | 12,048 (6.3) | 558 (0.3) | 478 (15.1) | 61 (1.7) |
| Smoking status | ||||
| Non-smoker | 79,056 (41.4) | 161,964 (96.3) | 658 (20.8) | 3,321 (95.0) |
| Former smoker | 29,888 (15.6) | 1,619 (1.0) | 987 (31.2) | 46 (1.3) |
| Current smoker | 82,255 (43.0) | 4,567 (2.7) | 1,519 (48.0) | 129 (3.7) |
| Physical activity | ||||
| Low | 95,495 (49.9) | 112,770 (67.1) | 2,539 (80.3) | 2,921 (83.6) |
| Medium | 78,139 (40.9) | 40,898 (24.3) | 573 (18.1) | 525 (15.0) |
| High | 17,565 (9.2) | 14,482 (8.6) | 52 (1.6) | 50 (1.4) |
| Antihypertensive therapy | 35,981 (18.8) | 42,188 (25.1) | 246 (7.8) | 355 (10.2) |
| Statin therapy | 6,124 (3.2) | 7,454 (4.4) | 18 (0.6) | 9 (0.3) |
| Body mass index, kg/m2 | 23.9±2.8 | 23.9±3.0 | 24.2±2.8 | 24.7±3.2 |
| Body mass index, kg/m2 | ||||
| <18.5 | 4,588 (2.4) | 3,927 (2.3) | 62 (2.0) | 47 (1.3) |
| 18.5–22.9 | 66,475 (34.8) | 65,248 (38.8) | 972 (30.7) | 1,019 (29.2) |
| 23.0–24.9 | 53,976 (28.2) | 44,110 (26.2) | 907 (28.7) | 893 (25.5) |
| 25.0–29.9 | 62,430 (32.7) | 49,447 (29.4) | 1,156 (36.5) | 1,315 (37.6) |
| ≥30.0 | 3,730 (2.0) | 5,418 (3.2) | 67 (2.1) | 222 (6.4) |
| Systolic BP, mm Hg | 128.0±17.2 | 124.2±18.5 | 120.6±16.6 | 118.2±18.8 |
| Diastolic BP, mm Hg | 81.0±11.4 | 77.2±11.8 | 81.4±10.9 | 77.4±11.5 |
| Systolic BP, mmHg | ||||
| <100 | 2,823 (1.5) | 7,005 (4.2) | 226 (7.1) | 489 (14.0) |
| 100–119 | 45,513 (23.8) | 54,858 (32.6) | 1,401 (44.3) | 1,578 (45.1) |
| 120–139 | 91,123 (47.7) | 68,943 (41.0) | 1,135 (35.9) | 944 (27.0) |
| 140–159 | 40,625 (21.2) | 28,597 (17.0) | 326 (10.3) | 384 (11.0) |
| ≥160 | 11,115 (5.8) | 8,747 (5.2) | 76 (2.4) | 101 (2.9) |
| Total cholesterol, mg/dL | 198.1±36.9 | 201.4±38.1 | 198.6±35.5 | 197.4±35.9 |
| Total cholesterol, mg/dL | ||||
| <240 | 167,175 (87.4) | 142,687 (84.9) | 2,756 (87.1) | 3,078 (88.0) |
| ≥240 | 24,024 (12.6) | 25,463 (15.1) | 408 (12.9) | 418 (12.0) |
| Fasting glucose, mg/dL | 91.0 (82.0–101.0) | 89.0 (81.0–98.0) | 83.0 (78.0–90.0) | 80.0 (76.0–85.0) |
| Fasting glucose, mg/dL | ||||
| <70 | 3,887 (2.0) | 3,440 (2.0) | 72 (2.3) | 127 (3.6) |
| 70–84 | 55,142 (28.8) | 54,681 (32.5) | 1,654 (52.3) | 2,431 (69.5) |
| 85–99 | 79,498 (41.6) | 74,599 (44.4) | 1,239 (39.2) | 861 (24.6) |
| 100–109 | 32,794 (17.2) | 23,564 (14.0) | 160 (5.1) | 61 (1.7) |
| ≥110 | 19,878 (10.4) | 11,866 (7.1) | 39 (1.2) | 16 (0.5) |
| GGT, U/L | 32.0 (21.0–54.0) | 16.0 (12.0–23.0) | 31.0 (20.0–53.0) | 15.0 (12.0–21.0) |
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
BP, blood pressure; GGT, γ glutamyl transferase.
Adjusted hazard ratio (95% confidence interval) for diabetes in the development cohort
| Variable | Men | Women |
|---|---|---|
| Age, yr | 1.04 (1.03–1.04) | 1.03 (1.03–1.04) |
| Family history of diabetes | 1.50 (1.43–1.58) | 1.57 (1.48–1.67) |
| Alcohol intake | NA | |
| Abstinent | 1.00 | |
| Low-medium | 0.92 (0.89–0.95) | |
| High | 1.06 (1.00–1.11) | |
| Smoking status | ||
| Non-smoker | 1.00 | 1.00 |
| Former smoker | 1.07 (1.03–1.12) | 1.27 (1.09–1.47) |
| Current smoker | 1.48 (1.43–1.52) | 1.31 (1.21–1.42) |
| Physical activity | ||
| Low | 1.00 | 1.00 |
| Medium | 0.88 (0.86–0.91) | 0.93 (0.90–0.97) |
| High | 0.87 (0.83–0.91) | 0.98 (0.93–1.03) |
| Antihypertensive therapy | 1.39 (1.35–1.44) | 1.47 (1.42–1.52) |
| Statin therapy | 1.30 (1.23–1.38) | 1.37 (1.30–1.45) |
| Body mass index, kg/m2 | ||
| <18.5 | 1.08 (0.97–1.19) | 1.01 (0.88–1.16) |
| 18.5–22.9 | 1.00 | 1.00 |
| 23.0–24.9 | 1.40 (1.35–1.45) | 1.38 (1.32–1.45) |
| 25.0–29.9 | 1.92 (1.86–1.99) | 1.91 (1.83–1.99) |
| ≥30.0 | 3.50 (3.27–3.75) | 2.90 (2.72–3.09) |
| Systolic BP, mm Hg | ||
| <100 | 0.89 (0.76–1.03) | 0.84 (0.74–0.95) |
| 100–119 | 1.00 | 1.00 |
| 120–139 | 1.16 (1.12–1.21) | 1.21 (1.16–1.26) |
| 140–159 | 1.29 (1.24–1.35) | 1.34 (1.28–1.41) |
| ≥160 | 1.41 (1.33–1.49) | 1.44 (1.35–1.53) |
| Total cholesterol, mg/dL | ||
| <240 | 1.00 | 1.00 |
| ≥240 | 1.20 (1.15–1.24) | 1.11 (1.07–1.15) |
| Fasting glucose, mg/dL | ||
| <70 | 0.94 (0.83–1.07) | 0.98 (0.85–1.13) |
| 70–84 | 1.00 | 1.00 |
| 85–99 | 1.24 (1.20–1.29) | 1.26 (1.20–1.31) |
| 100–109 | 2.00 (1.92–2.09) | 2.18 (2.08–2.29) |
| ≥110 | 3.65 (3.50–3.80) | 3.83 (3.65–4.03) |
| Log GGT | NA | 1.63 (1.59–1.67) |
NA, not applicable; BP, blood pressure; GGT, γ glutamyl transferase.
Fig. 1Calibration plots with C-statistics in the (A, B) development and (C, D) validation cohorts. Data markers represent the observed event rate (position on the y-axis) in relation to the predicted event rate (position on the x-axis); dotted lines, perfect calibration (i.e., observed=predicted).
Fig. 2Cumulative incidence of diabetes events according to (A) sex, (B) age, (C) body mass index, (D) systolic blood pressure, (E) fasting glucose, and (F) total cholesterol.